An interventional study of femoropopliteal revascularization for TASC C or TASC D lesion in Superficial Femoral Artery Stenosis, Claudication and Ischemic Leg, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment
This is a common care study. A study for evaluating the quality of balloon inflation and stent application will be performed in 2D angiography alone in the control group and then by 2D and OCT angiography for the experimental group. The benefit could be an improvement in the results of revascularization of femoropopliteal lesions thanks to OCT which allows a 3D visualization of the arterial lumen.
Exclusion Criteria:
Control group: an arteriography will be performed on the entire treated segment to assess the quality of the result, the application or not an active balloon will be left to the discretion of the operator. In case of application of the active balloon, a new arteriography before decision or not the use of stenting will be practiced. In case of stenting, an arteriographic final is performed.
Device: femoropopliteal revascularization for TASC C or TASC D lesion
Experimental group: an arteriography and OCT acquisition on the entire treated segment to ensure the quality of the result, the application or not of an active ball will be left. In case of application of the active balloon, a new arteriography and OCT acquisition before decision or not the use of stenting will be practiced. In case of stenting, a final arteriography and then OCT acquisition are performed.
Device: femoropopliteal revascularization for TASC C or TASC D lesion
Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
Primary patency rate at 1 year.
The permeability rate is defined by the echodoppler criteria: PVS\>2.4m/s or appearance of stenosis on the previously treated segment \>70%.
Time frame: at 12 months (+/- 2months)
Primary patency rate at 1 year.
Time frame: at 1month (+/- 10days), 6months (+/- 1month)
Target lesion revascularisation
corresponds to the occurrence of a re-intervention on the treated segment to maintain or restore permeability
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
Target vessel revascularisation
corresponds to the occurrence of a re-intervention on the previously treated artery, whatever the level, in order to maintain its permeability.
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
cost-effectiveness analyses
Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs.
Time frame: at 12 months (+/- 2months)
Rutherford scale considered ordinal variable
Rutherford grade of 2-4 for their target leg. The Rutherford scale is an indicator for the severity of Peripheral Vascular Disease: 0 = no symptoms, 6 = functional foot is no longer salvageable (leading to foot amputation).
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
Variation in Ankle Brachial Index between randomization and 1, 6, 12 months on the revascularized limb in the study.
Ankle-brachial index defined as the ratio of the blood pressure at the ankle to the blood pressure in the upper arm
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
Variation in quality of life assessed by Walk Impairment Questionnary between randomization and 1, 6, 12 months.
a questionnaire for evaluating walking impairment in patients Parameters: * difficulty walking a distance during the past month * difficulty walking at a certain speed during the past month * symptoms associated with walking impairment
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
Variation in quality of life assessed by EQ5D scores between randomization and 1, 6, 12 months.
overall score on a numeric scale "check the box that best describes your health today", 5 themes (mobility, autonomy of the person, common activities, pain / discomfort, anxiety / depression)
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
Limb Rescue Rate
Time frame: at 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille